Advertisement


Jeanne Tie, MD, MBChB, on Colon Cancer: New Data on ctDNA Guiding Adjuvant Therapy

2024 ASCO Annual Meeting

Advertisement

Jeanne Tie, MD, MBChB, of Peter MacCallum Cancer Centre, discusses data on survival and updated 5-year results from the DYNAMIC trial, which supports a role for circulating tumor DNA (ctDNA) analysis, including serial sampling, in the management of patients with stage II colon cancer (Abstract 108).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So the dynamic is a randomized trial looking at the utility of using CtDNA to guide adjuvant treatment in stage two colon cancer. The rationale behind the study is the fact that the role of adjuvant chemotherapy remains debatable in stage two colon cancer where surgery cured the majority of patients and to date, there has been very little evidence of survival benefit with the use of adjuvant chemotherapy. Our prior work have shown that detection of CtDNA after surgery is highly prognostic, where almost all patient recurred if left untreated. So this is a non-inferiority study that randomized patient to two-thirds receiving CtDNA guided management and one-third of standard management. So in the CtDNA guided group, patient with a positive result after surgery receive adjuvant chemotherapy and patient with a negative result were just observed. So the key findings from the study is that we have reduced the use of adjuvant chemotherapy by using CtDNA compared to standard management from 28% down to 15%, but we did not compromise recurrence-free survival. The updated results from dynamics showed that even at 5 years, the recurrence-free survival was 88.3% in the CtDNA guided group, and 87.2% with that of management of not using the blood test and the lower bound of the 95 confidence interval remains above the non-inferiority margin, again, confirming the non-inferiority of this approach. The overall survival between the two arms are similarly very favorable, ranging around 93%, which is very impressive. Intriguingly, we found that more than half the patient, substantial proportion of the death events in the study were not due to colorectal cancer recurrence resulting in a disease-specific survival, exceeding 97% across both arms. Another interesting finding is that we collected serial bloods on patient who have CtDNA positive and receive adjuvant chemotherapy. We found a very high clearance rate of 87.5% of CtDNA clearance following adjuvant chemotherapy, and patients who cleared a CtDNA had exceedingly good recurrence-free survival compared to patient who did not clear their CtDNA. So we also found that in untreated CtDNA negative T4 tumor, their overall survival is excellent at 19.6%. The implication for clinical practice is that using CtDNA to guide therapy compared to not having the blood test in stage two colon cancer can reduce the use of adjuvant chemotherapy without compromising patient's outcome and that CtDNA clearance rate is very high, supporting the benefit of adjuvant chemotherapy in this very high-risk population.

Related Videos

Clifford A. Hudis, MD, and Karen E. Knudsen, MBA: An ASCO–American Cancer Society Partnership to Benefit Patients

Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO), and Karen E. Knudsen, MBA, CEO of the American Cancer Society, discuss a newly launched collaboration between the organizations to make it simpler for patients to find authoritative cancer information online. The effort creates one of the largest and most comprehensive online resources for credible cancer information, available for free to the public on cancer.org.

 

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.

Gynecologic Cancers

Jean-Marc Classe, MD, PhD, on Ovarian Cancer: New Data on Lymphadenectomy From the CARACO Trial

Jean-Marc Classe, MD, PhD, of France’s Nantes Université, discusses phase III results showing that systematic lymphadenectomy should be omitted in patients with advanced epithelial ovarian cancer with clinically negative lymph nodes, as well as those undergoing neoadjuvant chemotherapy and interval complete surgery (LBA5505).

Multiple Myeloma

Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone

Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).

Lung Cancer

Narjust Florez, MD, and Suresh S. Ramalingam, MD, on EGFR-Mutated NSCLC: Update on Osimertinib and Chemoradiotherapy

Narjust Florez, MD, of the Dana-Farber Cancer Institute, and Suresh S. Ramalingam, MD, of Emory University School of Medicine, Winship Cancer Institute, discuss potentially practice-changing phase III results from the LAURA study. This trial showed that osimertinib after definitive chemoradiation therapy improved progression-free survival for patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC), suggesting this agent may represent a new standard of care in this setting (LBA4).

Advertisement

Advertisement




Advertisement